Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

NCT05911958 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT05911958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05911958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
July 5, 2023
Completion date
May 31, 2029
Enrollment
66 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2 low breast carcinoma